Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Augmenting the Anti‐Leukemic Activity of the BCL‐2 Inhibitor Venetoclax Through Its Transformation Into Polypharmacologic Dual BCL‐2/HDAC1 and Dual BCL‐2/HDAC6 Inhibitors

Drug Development Research(2025)10.1002/ddr.70084Source: DataRank Database

Augmenting the Anti‐Leukemic Activity of the BCL‐2 Inhibitor Venetoclax Through Its Transformation Into Polypharmacologic Dual BCL‐2/HDAC1 and Dual BCL‐2/HDAC6 Inhibitors is a research paper published in Drug Development Research (2025). On theSindex it has a DataRank of 0. It has been cited 5 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access5 citations

Download PDF

Cite:

Linked data & code

pdb doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 2.43)OA: hybridTopics (45)IDs (PubMed, PMC, OpenAlex)Annotations (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (7)

Christian Eberly,Brandon Drennen,Christopher C. Goodis,Zoe Wuyts,Curt I. Civin ORCID

Live enrichment

PubMed:40370107 PMC:PMC12079163 OpenAlex:https://openalex.org/W4410404696

NIGMS NIH HHS

Grant: T32 GM066706

NCI NIH HHS

Grant: R21 CA256314

National Institutes of Health.

National Institutes of Health

National Institutes of Health.

FWCI

2.43

Citation Percentile

0.9%

Citation Trend

2025

2026

hybridLicense: cc-by

journalhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ddr.70084

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ddr.70084

publisherhttps://analyticalsciencejournals.onlinelibrary.wiley.com/doi/pdf/10.1002/ddr.70084

journalhttps://doi.org/10.1002/ddr.70084

repositoryhttps://pubmed.ncbi.nlm.nih.gov/40370107

Fields of Study

Histone Deacetylase Inhibitors ResearchSynthetic Organic Chemistry MethodsProtein Degradation and InhibitorsHumansSulfonamidesProto-Oncogene Proteins c-bcl-2Histone Deacetylase InhibitorsHistone Deacetylase 6Bridged Bicyclo Compounds, HeterocyclicHistone Deacetylase 1Cell Line, TumorAntineoplastic AgentsDrug SynergismApoptosis

MeSH Terms

Histone Deacetylase 6Antineoplastic AgentsDrug SynergismHumansSulfonamidesApoptosisBridged Bicyclo Compounds, HeterocyclicProto-Oncogene Proteins c-bcl-2Cell Line, TumorHistone Deacetylase 1Histone Deacetylase Inhibitors

Keywords

VenetoclaxHDAC1Cancer researchHDAC6ChemistryPharmacologyPharmacophoreHistone deacetylase inhibitorHistone deacetylaseLeukemiaMedicineHistoneStereochemistryChronic lymphocytic leukemiaBiochemistryImmunologyCancerAMlHdacBcl‐2